Arch Biopartners Inc
XTSX:ARCH

Watchlist Manager
Arch Biopartners Inc Logo
Arch Biopartners Inc
XTSX:ARCH
Watchlist
Price: 1.25 CAD -7.41% Market Closed
Market Cap: 83.7m CAD

Net Margin

2 818.1%
Current
Improving
by 2 568.9%
vs 3-y average of 249.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
2 818.1%
=
Net Income
CA$-2.4m
/
Revenue
CA$-84.7k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
2 818.1%
=
Net Income
CA$-2.4m
/
Revenue
CA$-84.7k

Peer Comparison

Country Company Market Cap Net
Margin
CA
Arch Biopartners Inc
XTSX:ARCH
82.6m CAD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.2T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
238.3B USD
Loading...
US
Danaher Corp
NYSE:DHR
171B USD
Loading...
CH
Lonza Group AG
SIX:LONN
38B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.9B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
281.9B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
39.2B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
29B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.1B EUR
Loading...
No Stocks Found

Market Distribution

Higher than 99% of companies in Canada
Percentile
99th
Based on 4 909 companies
99th percentile
2 818.1%
Low
-9 940 586.9% — -85.9%
Typical Range
-85.9% — 5.5%
High
5.5% — 60 777.6%
Distribution Statistics
Canada
Min -9 940 586.9%
30th Percentile -85.9%
Median -7.8%
70th Percentile 5.5%
Max 60 777.6%

Arch Biopartners Inc
Glance View

Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.

ARCH Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
2 818.1%
=
Net Income
CA$-2.4m
/
Revenue
CA$-84.7k
What is Arch Biopartners Inc's current Net Margin?

The current Net Margin for Arch Biopartners Inc is 2 818.1%, which is above its 3-year median of 249.2%.

How has Net Margin changed over time?

Over the last 3 years, Arch Biopartners Inc’s Net Margin has increased from -7.5% to 2 818.1%. During this period, it reached a low of -184.8% on Sep 30, 2024 and a high of 2 818.1% on Jul 30, 2025.

Back to Top